A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation
ONCOLOGY · 2024
DOI: 10.46883/2024.25921022 ↗Kurz gefasst
Fallbericht in der Zeitschrift ONCOLOGY, 2024. Verfasst von Jonathan Q Trinh und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Mutation, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Trinh, J. Q., Banskota, S. U., & Marr, A. S. (2024). A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation. ONCOLOGY. https://doi.org/10.46883/2024.25921022
Vancouver
Trinh JQ, Banskota SU, Marr AS. A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation. ONCOLOGY. 2024. doi:10.46883/2024.25921022
BibTeX
@article{Trinh2024,
author = {Trinh, Jonathan Q and Banskota, Shristi Upadhyay and Marr, Alissa S},
title = {A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation},
journal = {ONCOLOGY},
year = {2024},
doi = {10.46883/2024.25921022}
}
EUVIMED